Table 1.
Cohort demographics, serum AMH concentrations and age-corrected AMH centiles according to CKD stage
| Demographics and AMH results | All CKD | CKD 1 | CKD 2 | CKD 3a | CKD 3b | CKD 4–5 |
|---|---|---|---|---|---|---|
| n | 163 | 30 | 37 | 26 | 31 | 39 |
| Age (years) | 36.5 | 33.2 | 38.3 | 38.0 | 34.8 | 41.7 |
| (29.9–42.9) | (25.9–36.8) | (30.0–44.8) | (30.6–42.3) | (30.7–44.1) | (34.5–44.9) | |
| Ethnicity, n (%) | ||||||
| White European | 84 (62) | 16 (64) | 17 (63) | 16 (67) | 17 (63) | 18 (55) |
| Black | 30 (22) | 5 (20) | 5 (19) | 6 (25) | 5 (19) | 9 (27) |
| Southeast Asian | 22 (16) | 4 (16) | 5 (19) | 2 (8) | 5 (19) | 6 (18) |
| eGFR (mL/min/1.73 m2) | 51 (31–80) | 116 (109–140) | 72 (65–80) | 52 (48–56) | 38 (34–41) | 15 (9–23) |
| Renal disease aetiology, n (%) | ||||||
| Non-lupus glomerular disease | 42 (26) | 11 (37) | 9 (24) | 6 (23) | 9 (29) | 7 (18) |
| Lupus vasculitis | 28 (17) | 10 (33) | 3 (8) | 4 (15) | 3 (10) | 8 (21) |
| Hereditary/congenital | 21 (13) | 2 (7) | 11 (30) | 1 (4) | 2 (6) | 5 (13) |
| Reflux | 14 (9) | 0 (0) | 3 (8) | 2 (8) | 4 (13) | 5 (13) |
| Diabetic nephropathy | 13 (8) | 2 (7) | 1 (3) | 2 (8) | 4 (13) | 4 (10) |
| Hypertensive/renovascular | 8 (5) | 0 (0) | 2 (5) | 3 (12) | 2 (6) | 1 (3) |
| Other | 15 (9) | 0 (0) | 4 (11) | 3 (12) | 2 (6) | 6 (15) |
| Unknown | 22 (13) | 5 (17) | 4 (11) | 5 (19) | 5 (16) | 3 (8) |
| Renal transplant, n (%) | ||||||
| Functioning | 37 (23) | 1 (3) | 3 (8) | 10 (38) | 14 (45) | 9 (23) |
| Non-functioning | 1 (1) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 1 (3) |
| Current dialysis, n (%) | 10 (6) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 10 (56) |
| Haemodialysis | 7 (4) | 7 (39) | ||||
| Peritoneal dialysis | 3 (2) | 3 (17) | ||||
| Regular menstruation, n/N (%) | 35/51 (69) | 8/11 (73) | 5/8 (64) | 5/8 (64) | 8/12 (67) | 9/12 (75) |
| Oestrogen-containing drug use, n/N (%) | 9/133 (7) | 2/24 (8) | 5/30 (17) | 0/20 (0) | 0/25 (0) | 2/34 (6) |
| Progesterone-containing contraceptive use, n/N (%) | 25/131 (19) | 4/24 (17) | 5/29 (17) | 3/20 (15) | 7/25 (28) | 6/33 (18) |
| Serum AMH (pmol/L) | 6.33 (1.90–15.65) | 10.06 (4.62–20.73) | 6.02 (1.79–12.85) | 4.27 (1.44–8.79) | 8.89 (4.99–19.36) | 5.29 (1.27–14.77) |
| Serum AMH (ng/mL) | 0.88 (0.27–2.19) | 1.41 (0.65–2.90) | 0.84 (0.25–1.80) | 0.60 (0.20–1.23) | 1.25 (0.70–2.71) | 0.74 (0.18–2.07) |
| AMH centile | 19 (8–53) | 30 (4–55) | 28 (10–53) | 11 (4–31) | 24 (14–59) | 15 (7–60) |
| AMH predictive of low response to gonadotrophin stimulation (AMH ≤5.4 pmol/L), n (%)a | 95 (58) | 9 (30) | 18 (47) | 17 (65) | 8 (26) | 20 (51) |
Values are median (IQR) unless stated.
a
National Institute for Health and Care Excellence advise that AMH ≤5.4 pmol/L (Beckman-Coulter assay) is used to predict a low ovarian response to gonadotrophin stimulation [5].